Published in Metab Brain Dis on March 04, 2014
Study of Rifaximin in Minimal Hepatic Encephalopathy | NCT01069133
Gut/brain axis and the microbiota. J Clin Invest (2015) 1.64
Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci (2014) 1.47
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol (2015) 0.88
The role of microbiota in hepatic encephalopathy. Gut Microbes (2014) 0.85
Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep (2016) 0.85
Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol (2014) 0.83
A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy. Metab Brain Dis (2016) 0.75
Brain Training with Video Games in Covert Hepatic Encephalopathy. Am J Gastroenterol (2016) 0.75
Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol (2017) 0.75
Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage (2004) 49.54
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
Reproducibility of quantitative tractography methods applied to cerebral white matter. Neuroimage (2007) 7.14
Temporal dynamics of brain activation during a working memory task. Nature (1997) 6.66
Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed (2001) 6.56
Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage (2007) 5.23
Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Proc Natl Acad Sci U S A (1999) 4.62
Localization of a human system for sustained attention by positron emission tomography. Nature (1991) 3.35
Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cogn Affect Behav Neurosci (2001) 3.19
Neuropsychological characterization of hepatic encephalopathy. J Hepatol (2001) 3.12
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol (2010) 2.85
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology (2006) 2.62
Evidence for a two-stage model of spatial working memory processing within the lateral frontal cortex: a positron emission tomography study. Cereb Cortex (1996) 2.50
Dissociation of human mid-dorsolateral from posterior dorsolateral frontal cortex in memory processing. Proc Natl Acad Sci U S A (1993) 2.40
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol (2004) 2.04
Intrinsic connections and architectonics of posterior parietal cortex in the rhesus monkey. J Comp Neurol (1982) 1.88
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology (2010) 1.58
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Characteristics of minimal hepatic encephalopathy. Metab Brain Dis (2004) 1.47
Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis (2005) 1.27
A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis (2012) 1.21
Bilateral activation of fronto-parietal networks by incrementing demand in a working memory task. Cereb Cortex (1997) 1.20
Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. Neuroimage (2004) 1.10
Neural mechanism of cognitive control impairment in patients with hepatic cirrhosis: a functional magnetic resonance imaging study. Acta Radiol (2007) 1.06
Altered brain functional connectivity in patients with cirrhosis and minimal hepatic encephalopathy: a functional MR imaging study. Radiology (2012) 1.04
Differential effects of temporal pole resection with amygdalohippocampectomy versus selective amygdalohippocampectomy on material-specific memory in patients with mesial temporal lobe epilepsy. Epilepsia (2007) 1.03
Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. J Hepatol (2012) 1.01
Spatial working memory dysfunction in minimal hepatic encephalopathy: an ethology and BOLD-fMRI study. Brain Res (2012) 0.92
Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol (2013) 0.88
Multimodality MR imaging findings of low-grade brain edema in hepatic encephalopathy. AJNR Am J Neuroradiol (2012) 0.88
Memory for famous faces and the temporal pole: functional imaging findings in temporal lobe epilepsy. Epilepsy Behav (2006) 0.87
Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy. Am J Gastroenterol (2008) 0.87
Modulation of neural activation following treatment of hepatic encephalopathy. Neurology (2013) 0.86
Common neural recruitment across diverse sustained attention tasks. PLoS One (2012) 0.84
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A (2008) 3.39
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology (2008) 2.57
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Racial/ethnic differences in the experience of chronic pain. Pain (2002) 2.40
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology (2012) 2.31
Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol (2011) 2.23
Steroid use in acute liver failure. Hepatology (2013) 2.23
Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 2.20
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol (2013) 2.14
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med (2002) 2.00
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol (2012) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87